We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| H Lundbeck AS (PK) | USOTC:HLUYY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 22.00 | 22.00 | 30.13 | 0.00 | 01:00:00 |
From Jun 2019 to Jun 2024
By Tess Stynes
Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and H. Lundbeck A/S (HLUYY, LUN.KO) said their Azilect treatment for Parkinson's disease in combination with dopamine agonist therapy met its primary endpoint in an 18-week study.
The study data "continue to clarify the clinical profile of Azilect and the role it plays in helping to meet the needs of those living with [Parkinson's disease], at multiple points in the progression of their disease," said Dr. Michael Hayden, president of global research and development and chief scientific officer at Teva.
Azilect--or rasagiline--is indicated for the treatment of the signs and symptoms of Parkinson's disease both as initial standalone therapy and in combination with levodopa later in the disease.
The study data will be presented Wednesday at the 65th American Academy of Neurology Annual Meeting in San Diego.
Teva's American depositary shares were up 26 cents at $40.25 in premarket trading. H. Lundbeck's ADSs closed Tuesday at $17.46 and were inactive premarket.
Write to Tess Stynes at Tess.Stynes@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year H Lundbeck AS (PK) Chart |
1 Month H Lundbeck AS (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
